AR115998A1 - Polipéptidos anti-her2 y métodos de uso de los mismos - Google Patents

Polipéptidos anti-her2 y métodos de uso de los mismos

Info

Publication number
AR115998A1
AR115998A1 ARP190102390A ARP190102390A AR115998A1 AR 115998 A1 AR115998 A1 AR 115998A1 AR P190102390 A ARP190102390 A AR P190102390A AR P190102390 A ARP190102390 A AR P190102390A AR 115998 A1 AR115998 A1 AR 115998A1
Authority
AR
Argentina
Prior art keywords
her2
variable region
methods
antibody
bbb
Prior art date
Application number
ARP190102390A
Other languages
English (en)
Inventor
Joy Yu Zuchero
Jonathan Sockolosky
Joseph W Lewcock
Wanda Kwan
Mark S Dennis
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of AR115998A1 publication Critical patent/AR115998A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a constructos anti-HER2, tales como proteínas de fusión de dímero-anticuerpo de región variable polipéptido Fc que cruzan el BBB y se unen a HER2 en el parénquima cerebral. En algunas realizaciones, los constructos anti-HER2 (por ejemplo, las proteínas de fusión de dímero-anticuerpo de región variable polipéptido Fc) conservan la función efectora al unirse a HER2, pero no agotan sustancialmente los reticulocitos in vivo. La presente descripción también se refiere a métodos para transcitar una región variable de anticuerpo anti-HER2 a través de BBB y tratar cánceres HER2 positivos y lesiones metastásicas de los mismos.
ARP190102390A 2018-08-22 2019-08-22 Polipéptidos anti-her2 y métodos de uso de los mismos AR115998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22

Publications (1)

Publication Number Publication Date
AR115998A1 true AR115998A1 (es) 2021-03-25

Family

ID=67989062

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102390A AR115998A1 (es) 2018-08-22 2019-08-22 Polipéptidos anti-her2 y métodos de uso de los mismos

Country Status (15)

Country Link
US (1) US20220002436A1 (es)
EP (1) EP3840781A1 (es)
JP (1) JP2021534220A (es)
KR (1) KR20210074279A (es)
CN (1) CN113286610A (es)
AR (1) AR115998A1 (es)
AU (1) AU2019326545A1 (es)
BR (1) BR112021002953A2 (es)
CA (1) CA3141815A1 (es)
EA (1) EA202190603A1 (es)
IL (1) IL280922A (es)
MX (1) MX2021001976A (es)
SG (1) SG11202101436SA (es)
TW (1) TW202017947A (es)
WO (1) WO2020041604A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020508049A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 操作されたトランスフェリン受容体結合ポリペプチド
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
JP2023507846A (ja) 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
BR112022013756A2 (pt) 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
IL295729A (en) * 2020-02-19 2022-10-01 Denali Therapeutics Inc Bispecific engineered anti-2her proteins, preparations containing them and their uses
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN118119402A (zh) * 2021-08-25 2024-05-31 戴纳立制药公司 工程化抗her2双特异性蛋白
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240087579A (ko) * 2022-12-08 2024-06-19 주식회사 아델 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6219956B2 (ja) * 2012-08-29 2017-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 血液脳関門シャトル
JP2016501881A (ja) * 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CN107531788B (zh) * 2015-06-24 2022-06-21 豪夫迈·罗氏有限公司 对her2和血脑屏障受体特异性的三特异性抗体及使用方法
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
JP2020508049A (ja) * 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 操作されたトランスフェリン受容体結合ポリペプチド
CN110520440A (zh) * 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法

Also Published As

Publication number Publication date
AU2019326545A1 (en) 2021-03-11
SG11202101436SA (en) 2021-03-30
EA202190603A1 (ru) 2021-07-14
KR20210074279A (ko) 2021-06-21
US20220002436A1 (en) 2022-01-06
MX2021001976A (es) 2021-06-08
CN113286610A (zh) 2021-08-20
TW202017947A (zh) 2020-05-16
WO2020041604A1 (en) 2020-02-27
CA3141815A1 (en) 2020-02-27
EP3840781A1 (en) 2021-06-30
BR112021002953A2 (pt) 2021-05-11
IL280922A (en) 2021-04-29
JP2021534220A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
AR115998A1 (es) Polipéptidos anti-her2 y métodos de uso de los mismos
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CO2019003945A2 (es) Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1
ECSP17054182A (es) Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
CL2016003040A1 (es) Moléculas de unión tri-específicas y métodos de uso de las mismas.
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2022000803A2 (es) Anticuerpos que se fijan a gprc5d
ECSP18073836A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
PE20200486A1 (es) Anticuerpos anti-cd33 y metodos para utilizarlos
CO2018014325A2 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201690299A1 (ru) СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
PE20181310A1 (es) Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estos
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
NI201300099A (es) Anticuerpos anti péptidos citosólicos
EA201591700A1 (ru) Гибридные белки апелина и их применение
DOP2009000167A (es) Vacuna
CO2022000804A2 (es) Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
MX2020004220A (es) Anticuerpos anti-glico-muc1 y sus usos.